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The antiretroviral efﬁcacy of 3#-azido-3#-deoxythymidine
(AZT) is dependent upon intracellular mono-, di-, and triphos-
phorylation and incorporation into DNA in place of thymidine.
Thymidine kinase 1 (TK-1) catalyzes the ﬁrst step of this pathway.
MOLT-3, human lymphoblastoid cells, were exposed to AZT
continuously for 14 passages (P1–P14) and cultured for an
additional 14 passages (P15–P28) without AZT. Progressive and
irreversible depletion of the enzymatically active form of the TK-1
24-kDa monomer with loss of active protein was demonstrated
during P1–P5 of AZT exposure. From P15 to P28, both the 24- and
the 48-kDa forms of TK-1 were undetectable and a tetrameric
96-kDa form was present. AZT-DNA incorporation was observed
with values of 150, 133, and 108 molecules of AZT/10
6 nucleotides
at the 10mM plasma-equivalent AZT dose at P1,P 5, and P14,
respectively. An exposure-related increase in the frequency of
micronuclei (MN) was observed in cells exposed to either 10 or
800mM AZT during P1–P14. Analysis of the cell cycle proﬁle
revealed an accumulation of S-phase cells and a decrease in
G1-phase cells during exposure to 800mM AZT for 14 passages.
When MOLT-3 cells were grown in AZT-free media (P15–P29),
there was a reduction in AZT-DNA incorporation and MN forma-
tion; however, TK-1 depletion and the persistence of S-phase delay
were unchanged. These data suggest that in addition to known
mutagenic mechanisms, cells may become resistant to AZT par-
tially through inactivation of TK-1 and through modulation of cell
cycle components.
Key Words: nucleoside analog; antiretrovirals; thymidine
kinase.
The genotoxicity of the DNA chain–terminating nucleoside
reverse transcriptase inhibitors (NRTIs) has been amply demon-
strated (International Agency for Research on Cancer, 2000), but
speciﬁc underlying mechanisms other than DNA incorporation
and mutagenesis are unclear. Since clinical NRTI therapy is
administered long term and because human bone marrow is
a target for NRTI toxicity (Richman et al.,1 9 8 7 ; Yarchoan et al.,
1989), human lymphoblastoid (MOLT-3) cells were used here
to study the genotoxic mechanisms of long-term NRTI exposure.
Itiswellestablishedthat3#-azido-3#-deoxythymidine(AZT)acts
as an HIV-1 reverse transcriptase inhibitor (Mitsuya et al.,1 9 8 5 )
by DNA incorporation that is required for chain termination and
by blocking the nucleotide-binding site of the HIV-1 reverse
transcriptase (Furman et al.,1 9 8 6 ).
Thymidine kinase 1 (TK-1) catalyzes the monophosphor-
ylation of AZT in the pathway of activation to DNA
incorporation and is considered to be the rate-limiting step in
NRTI metabolism. In cultured human cells, AZT resistance has
been reported to be correlated with decreases in TK-1 activity
(Avramis et al., 1993; Han et al., 2004) and hypermethylation
of the TK1 gene (Nyce et al., 1993; Wu et al., 1995). TK-1
exists intracellularly as an active monomeric form (24 kDa), an
inactive dimeric form (48 kDa), and an inactive cytosolic
tetramer (96 kDa) (Sherley and Kelly, 1988).
The triphosphorylated AZT becomes incorporated into virus
and host DNA in place of thymidine, inducing chain
termination that results in DNA fragmentation and the
formation of micronuclei (MN) (Olivero, 2007). Induction of
MN occurring as a result of exposure to AZT has been reported
in many different studies using various cell cultures and animal
species. For example, increased levels of MN were reported in
CD4 lymphocytes (Stern et al., 1994) and human lymphocytes
and Chinese hamster ovary cells (Gonzalez and Larripa, 1994),
HeLa cells (Aruna and Jagetia, 2001), and human H9 cells
(Agarwal and Olivero, 1997) all as a result of exposure to AZT.
In addition, an increase in frequency of erythrocyte MN was
observed in mouse pups exposed to AZT plus the NRTI
didanosine (ddI) during gestation and after birth (Bishop et al.,
2004; Dertinger et al., 1996; Witt et al., 2004) and in TK
þ/
þ
and TK
þ/
  mice (Dobrovolsky et al., 2005). The formation of
AZT-DNA incorporation and AZT-induced MN suggests that
chronic AZT exposure may induce mutations and functional
  The Author 2010. Published by Oxford University Press on behalf of the Society of Toxicology. For permissions, please email: journals.permissions@oxfordjournals.org.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5), which permits
unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.alterations in DNA replication. Increase in the frequency of
complete Tk gene deletions following exposures to AZT and
ddI have been reported (Meng et al., 2002) in vitro and in vivo
(Von Tungeln et al., 2004). Furthermore, mutational analysis
suggests that AZT induces a unique pattern of mutations in the
Tk gene of mice and that the major mechanisms of AZT-
induced mutagenesis involve deletion and recombination
(Mittelstaedt et al., 2004).
Here, we pursued mechanistic studies exploring consequen-
ces of prolonged AZT exposures using high concentrations of
AZT that have been shown to induce genotoxicity and
minimum cell death and compared those to therapeutic doses.
Additionally, we have explored the persistence of AZT-
induced effects once the exposure was terminated. To this
end, we cultured MOLT-3 cells continuously in the presence of
AZT for 14 passages (P14), followed by an additional 15
passages in the absence of the drug. We explored cell cycle
parameters by ﬂow cytometry and DNA damage by a radioim-
munoassay (RIA) able to detect AZT incorporated into DNA
and by documenting MN formation. Additionally, we in-
vestigated the role of chronic AZT exposure as a modulator of
TK-1 oligomerization and functional capacity.
MATERIALS AND METHODS
Cell culture and treatment. The human lymphoblastoid cell line MOLT-3
(ATCC, Manassas, VA) was cultured using Rossman-Park-Memorial-Institute
(RPMI) 1640 medium supplemented with 10% fetal bovine serum (ATCC).
AZT (Sigma-Aldrich Co., St Louis, MO) exposures were performed in 75-cm
2
plastic culture ﬂasks. AZT was dissolved in PBS (pH 7.2) (Biosource,
Rockville, MD), and the ﬁnal concentration was calculated from absorbance at
266 nm with a molar extinction coefﬁcient of 11,500. Triplicate experiments
were performed to assess the incorporation of 0, 5, 10, 50, 100, 200, and
800lM AZT into MOLT-3 cell DNA, for up to 14 passages. In a separate
study, ﬁve different batches of MOLT-3 cells were exposed continuously to
800lM AZT for up to P14, and for three of those ﬁve experiments, AZT was
removed at P14 and cells were grown for an additional 15 passages (to P29)i n
the absence of drug. Finally, in a repeat experiment, MOLT-3 cells were
exposed to 10lM AZT, a human plasma level concentration, for 14 passages.
Throughout this study, unexposed cells, cultured simultaneously and in
parallel with every experimental passage, were used as controls for the end
points examined. To simplify the written explanation, we have designated all
unexposed passages as ‘‘PU’’; however, it is important to recognize that for
each experiment an appropriate unexposed control of the same passage was
used for comparison.
Cytotoxicity analysis and time to subculture. MOLT-3 cells, from ﬁve
independent trials, were collected 24 h after exposure to either 0 or 800lM
AZT. For each experiment, cells were counted twice in a Coulter Counter
(Coulter Electronics Limited, UK), and cell counts from drug-exposed ﬂasks
were compared with those from the unexposed ﬂasks. Survival in exposed cells
was expressed as percentage of survival in unexposed cells. In addition to
counting, survival was established by trypan blue exclusion, with numbers of
viable cells compared in exposed and unexposed cells. A separate observation
was made in 15 independent trials to establish time to subculture. The ability of
the cells to proliferate was also evaluated based on color changes in the culture
medium indicated by phenol red. Typically, a yellowish color is observed
when a critical amount of cells is present, point at which the cells were
subcultured.
Preparation of DNA and measurement of AZT incorporated into DNA by
RIA. DNA from unexposed cells and AZT-exposed cells at P1,P 5, and P14
was obtained by nonorganic isolation (Chemicon International, Temecula, CA).
The incorporation of AZT into MOLT-3-DNA was determined in cells exposed
to 0, 5, 10, 50, 100, 200, and 800lM AZT by an AZT-RIA (Olivero et al.,
1994). Brieﬂy, a rabbit polyclonal anti-AZT antibody (Sigma-Aldrich Co.),
which also recognizes AZT in DNA (Olivero et al., 1994), was reconstituted,
diluted 1:7500, and incubated with MOLT-3-DNA for 90 min at 37 C. An
aliquot (100 ll) containing ~20,000 cpm of [
3H]AZT tracer (16 Ci/mmol;
Moravek Biochemicals Inc., Mountain View, CA) was added to each tube
together with 100 ll of the secondary antibody, goat anti-rabbit immunoglob-
ulin G (IgG; Sigma-Aldrich Co.), and reconstituted in 12 ml of 2-amino-2-
hydroxymethyl-propane-1,3-diol (Tris) buffer (pH 8.00). The mixture was
incubated for 25 min at 4 C, centrifuged at 1942 3 g for 15 min at 4 C, and the
resulting supernatant was decanted. The pellets were dissolved in 200 ll 0.1M
NaOH, transferred to scintillation vials containing 6 ml Ecolite (MP, Irvine,
CA), and counted in a liquid scintillation counter. The amount of standard
AZT, added to 3 lg of unexposed carrier MOLT-3-DNA, required to inhibit
antibody binding by 50% was 2.86 ± 0.9 (average ± SD, n ¼ 12) pmol AZT/
tube. The lower limit of detection was 4.2 molecules of AZT/10
6 nucleotides.
MN assay. In separate experiments, MOLT-3 cells were exposed to 0, 10,
and 800lM AZT and collected at P1,P 4,P 5, and P14. MOLT-3 cells, exposed
on three separate occasions to 0 and 800lM AZT, were collected at P1,P 4,P 5,
P14, and P27. Cells from all the treatments and unexposed cells were centrifuged
and pellets were ﬁxed with 70% alcohol to obtain suspensions of 8 3 10
4 cells/ml
media. Ten slides/passage/experiment were obtained by centrifugation of 50 ll
of the cell suspension/slide (~4000 cells) using a cytocentrifuge (Shandon
Cytospin 2; Thermo Fisher Scientiﬁc Inc., Waltham, MA). Cells were stained
with a 5% solution of Giemsa stain in PBS (pH 7.4) for 5 min. MN were scored
in 1000 MOLT-3 cells from 10 slides/passage.
Flow cytometric analysis of cell cycle parameters. MOLT-3 cells were
exposed on three separate occasions to 800lM AZT during P1–P14 and then
grown in AZT-free media for additional 10 passages. Cells were collected at
every passage, pelleted, and washed with RPMI 1640 without serum before
they were ﬁxed in 1 ml 70% ice-cold ethanol, gently dropped while vortexing.
Following an overnight ﬁxation at 4 C, cells were pelleted by centrifugation
and incubated with Ribonuclease A (Sigma-Aldrich Co.) at room temperature
for 20 min. Propidium iodide (20–50 lg/ml) (Molecular Probes, Eugene, OR)
was added to each cell suspension, and cells were kept in the dark at 4 C
overnight. Cells were passed through a ﬂuorescence-activated cell sorter
(FACSCalibur; BD Biosciences, San Jose, CA) using the doublet discrimina-
tion module, and data were acquired using CellQuest (BD Biosciences)
software. The cell cycle was modeled using ModFit software (Venty Software,
Topsham, ME). Percentages of cells in G0–G1, S, and G2–M phases were
calculated directly by the software.
Western blot for TK-1 protein analysis. Aliquots of unexposed and AZT-
exposed MOLT-3 cells from each passage were lysed in radio-immune
precipitation assay buffer (50mM Tris-HCl [pH 7.6], 150mM NaCl, 0.25%
SDS, 1% Triton X-100, 1mM EDTA, and 0.5% Nonidet P-40 [NP-40]; Fluka
Chemicals, Milwaukee, WI) with the addition of protease inhibitor tablets
(Complete; Roche Diagnostics, Indianapolis, IN) for 30 min on ice, followed by
sonication with an ultrasonic processor at a 20% amplitude with a 3-mm microtip
(Sonics VC 750; Sonics and Materials Inc., Newtown, CT) for three pulses of
10 s each. Proteins were quantiﬁed by Bradford reaction (Bio-Rad, Hercules,
CA). Samples were resolved on a 10% Bis-Tris vertical polyacrylamide gel
(NuPage; Invitrogen) and then transferred to a polyvinylidene ﬂuoride membrane
(Immobilon-P; Millipore, Billerica, MA). Membranes were allowed to dry
overnight and then were blocked with phosphate buffer saline 0.1% tween
containing 5% nonfat dry milk. A TK-1 monoclonal antibody (QED Biosciences,
San Diego, CA) was used to incubate the membrane overnight at 4 C. After
incubation with an anti-mouse IgG-horseradish peroxidase (HRP)–conjugated
secondary antibody (Novus Biologicals, Littleton, CA), the membrane was
processed for chemiluminescence with an Enhanced Chemiluminescence
110 OLIVERO ET AL.Western Blotting Detection Kit (Amersham Biosciences, Buckinghamshire, UK).
Controls for loading were carried out after stripping the membrane (Restore;
Invitrogen) using a mouse anti-actin antibody (Chemicon International) followed
by an anti-mouse IgG-HRP–conjugated secondary antibody (Novus Biologicals).
Signal was revealed using electrochemiluminescence Western Blotting Detection
Reagents as previously described (Olivero et al., 2008). Images were captured
using a Lumi-imager (Roche Diagnostics).
Radiochemical enzyme–speciﬁc activity assay for TK-1. Pellets from
AZT-exposed cell suspensions (3 3 10
7 cells) collected at different passages in
three separate experiments were resuspended in 1 ml of ice-cold extraction
buffer (50mM Tris-HCl [pH 7.6], 2mM dithiothreitol [DTT], 1 protease
inhibitor cocktail tablet [Roche Diagnostics], 20% glycerol, and 0.5% NP-40).
Cell suspensions were frozen and thawed three times to improve the lysis
process, and sonicated cell lysates were centrifuged for 10 min at 18,000 3 ga t
4 C. The supernatant was kept on ice and analyzed for protein concentration as
described above using the Bradford reaction. Diethylaminoethyl cellulose
ﬁlter discs (Whatman, Maidston, UK) were immersed in 10lM AZT-
monophosphate (MP) for 10 min and allowed to dry completely. The reaction
mixture (50mM Tris-HCl [pH 7.6], 2mM DTT, 5mM MgCl2, 5mM ATP,
10mM NaF, and 20lM[ H
3]-AZT; 12 Ci/mmol; Moravek Radiochemicals,
Brea, CA) was used to incubate the protein extract at 37 C for 20 min. After
that time, 20 ll of the suspension was spotted on the pretreated DEAE discs.
The discs were allowed to air dry and washed three times with ammonium
formate, transferred to liquid scintillation vials, and eluted with 0.1M HCl þ
0.2M NaCl solution for 30 min to release the [
3H]-AZT-MP. The eluate was
diluted in liquid scintillation solution, and radioactivity was counted. TK-1
activity (counts per minute) was measured as directly proportional to the
radioactivity obtained (Arner et al., 1992).
Phosphorylation of [
3H]-thymidine during cell growth. Control cells and
cells treated with 800lM AZT for 1, 45, and 59 passages were incubated for
30 min with [
3H]-thymidine. Cells were harvested and lysed in 5%
trichloroacetic acid. After 10 min on ice, the extracts were centrifuged at
a 3-min centrifugation at 2000 3 ga t4  C. A measured volume of the resultant
supernatant was neutralized by addition of AG-11A8 resin (0.5 g/ml extract),
ﬁltered, and the labeled deoxynucleoside/deoxynucleotide pools were analyzed
by high pressure liquid chromatography as described (McKee et al., 2004).
RESULTS
Cytotoxicity and Time to Subculture for MOLT-3 Cells
Exposed Chronically to AZT
MOLT-3 cells that were collected 24 h after exposure to 0,
10, or 800lM AZT exhibited a survival of 100, 81.9, and
69.2%, respectively. In separate experiments, time to sub-
culture was assessed in MOLT-3 cells during the course of
14 passages of continuous exposure to 0, 10, or 800lM AZT
(Fig. 1, open circles). In unexposed cells, passaging took place
daily, and in AZT-exposed cells at P2–P5, a delay in the cell
cycle was observed. However, Figure 1 shows that by ﬁve
passages of AZT exposure, the rate of doubling was altered so
that conﬂuence was observed by 2-day intervals for P5–P14.
Similar proﬁle was observed for long-term MOLT-3 cells
exposed to 10lM AZT.
During 14 passages of chronic exposure to 800lM AZT, the
activity of TK-1, measured by the capacity to phosphorylate
thymidine, revealed an abrupt decrease as early as P1, which
lasted until P14 (Fig. 1). Insets in Figure 1 show Western blots
of monomeric (24 kDa) TK-1 from extracts obtained at the
same passages for which time to conﬂuence and activity were
measured. The inserts show unexposed cells and cells exposed
to AZT for the passages indicated and were obtained from the
FIG. 1. Comparison of time to conﬂuence (circles) and TK-1–speciﬁc activity (% of control [triangles]) for MOLT-3 cells exposed continuously to 800lM
AZT. Time to conﬂuence was determined visually, and TK-1 phosphorylation was obtained by radiolabeling assay (see ‘‘Materials and Methods’’ section). Insets
show expression of monomeric 24-kDa TK-1 by Western blots, where the ‘‘ctrl’’ cells were unexposed and the exposed passages are indicated. For loading
control, see Figure 5.
AZT EXPOSURE ON HUMAN LYMPHOBLASTOID CELLS 111Western blot presented in Figure 5a. The reduction of TK-1
activity with continued culture time in the presence of AZT is
clearly documented here.
Incorporation of AZT into MOLT-3 Cell DNA
An RIA was used to determine the amount of AZT
incorporated into DNA at different passages. Figure 2 shows
AZT-DNA incorporation values for MOLT-3 cells exposed to
5, 10, 50, 100, 200, and 800lM AZT for 1, 5, and 14 passages.
Incorporation of AZT was observed at all passages with all
doses, with maximum incorporation, 246 molecules AZT/10
6
nucleotides, at P5 with the 200lM dose. For the 800lM AZT
dose, the highest incorporation was also observed at P5 with
171 molecules AZT/10
6 nucleotides. Figure 2 shows no
obvious dose response either with dose or with increasing
passage number. In an additional experiment, MOLT-3 cells
originally exposed to 800lM AZT for 14 passages were
subsequently cultured in AZT-free media, for an additional 12
passages. No detectable AZT-DNA incorporation remained
after these cells were cultured in the absence of AZT for 12
passages (data not shown).
Statistical Interpretation
Application of linear regression to the mean levels of AZT-
DNA incorporation at P1 showed a positive trend with an R
value of 0.737. However, the data did not pass the normality
test (p ¼ 0.03) due to the mean value at 10lM AZT. If the
latter value for 10lM AZT is excluded, then the data for the
remaining AZT concentrations pass a Normality Test, and
a highly positive linear regression (R ¼ 0.985) is observed at
P1. One-way ANOVA was used in addition to the Student’s
t-test to compare the data among groups on the MN experi-
ments (Table 2), and the p value was of 0.0001.
DNA Damage Assessed by the MN Assay
The MN assay was performed as one indicator of AZT-
induced DNA damage. The induction of MN in MOLT-3 cells
exposed to 10lM AZT (Fig. 3) and 800lM AZT (Fig. 3)i s
shown for passages 0, 1, 4, 5, and 14. In Figure 3 statistically
signiﬁcant differences were observed for all the AZT-exposed
passages compared to the unexposed controls (p values ¼
0.016, 0.0003, 0.0078, and 0.0022 for P1,P 4,P 5, and P14,
respectively). Additionally, a comparison among the un-
exposed controls cultured in parallel for P1,P 4,P 5, and P14
showed no statistical signiﬁcance (p ¼ 0.084)
In cells exposed to 800lM AZT at P1,P 4,P 5, and P14, the
MN (per 1000 cells examined) reached values of 20, 61, 38,
and 35, respectively, a signiﬁcant increase for passage 1
(p ¼ 0.02) compared to the untreated control (PU) and highly
signiﬁcant increase for P4 (p ¼ 0.0001), P5 (p ¼ 0.0002), and
P14 (p ¼ 0.0001); p < 0.05 for each passage compared to PU.
However at P27, after 13 passages of culturing in the absence of
drug, MN values returned to control levels (8/1000 cells)
(Table 2).
Cell Cycle Analysis of MOLT-3 Cells Exposed Chronically to
800lM AZT
Evaluation of changes in the MOLT-3 cell cycle proﬁle was
carried out by ﬂow cytometry in cells exposed long term to
AZT. Table 1 shows percentages of cells in G0–G1, S, and G2
phases determined in untreated (control) cells and in cells
exposed to 800lM AZT at P1 and P14. Table 1 also shows
values for cells at P24, which were exposed to AZT for 15
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FIG. 2. AZT-DNA incorporation measured by an AZT-speciﬁc RIA.
AZT-DNA incorporation for MOLT-3 cells exposed to 0, 5, 10, 20, 100, 200,
and 800lM AZT at P1 (white bars), P5 (gray bars), and P14 (black bars). Each
column shows the number of molecules of AZT incorporated into MOLT-3 cell
DNA from cells exposed continuously to each dose. Values are mean ± SD
from three experiments.
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FIG. 3. Frequency of MN (MN cells/1000 MOLT-3 cells). MN were
scored at P0,P 1,P 4,P 5, and P14 of exposure to 10lM AZT (white bars), 800lM
AZT (gray bars), and in cells at P27 (14 passages with 800lM AZT and 13
consecutive passages with no AZT, dark bar). Values are mean ± SD from three
experiments. Comparison of MN induced by 10lM AZT frequency by
Student’s t-test showed a signiﬁcant increase for passage 1 (p ¼ 0.016)
compared to the untreated control (P0), P4 (p ¼ 0.0003), P5 (p ¼ 0.0078), and
P14 (p ¼ 0.0022). Values are mean ± SD from three experiments. Comparison
of MN frequency induced by 800lM AZT by Student’s t-test showed
a signiﬁcant increase for passage 1 (p ¼ 0.02) compared to the untreated
control (P0) and highly signiﬁcant increase for P4 (p ¼ 0.0001), P5
(p ¼ 0.0002), and P14 (p ¼ 0.0001).
112 OLIVERO ET AL.passages and grown for 10 subsequent passages in medium
without AZT. An accumulation of cells in S-phase was
observed with AZT exposure and was not reversed during
growth for 10 passages in the absence of AZT. The increase of
cells in S-phase was accompanied by a decrease of cells in G1.
Although the most dramatic AZT-induced S-phase change was
from 42 to 57% observed at P1, cells at P14 and P24 also
exhibited a statistically signiﬁcant increase in S-phase accu-
mulation. A marked decrease in percent of cells in G1 was
found for cells exposed to 800lM AZT for a single passage;
30% of AZT-exposed cells at P1 were in G1 compared to 46%
of unexposed cells at P0 in G1 (p ¼ 0.05) (Tables 1 and 2).
Additionally, P1 cells in G1 and S-phase were altered more
substantially than cells at P14 and P26.
Reduction of TK-1 Protein Level with Long-term Culture of
MOLT-3 Cells in the Presence of AZT
Cell lysates from consecutive passages of MOLT-3 cells
exposed to 800lM AZT were processed for Western blot
analysis using an anti-TK-1 antibody. Figure 4 shows the
expression of TK-1 protein in its inactive dimeric (48 kDa) and
active monomeric (24 kDa) forms, for unexposed (P0) cells and
cells exposed to 800lM AZT from P1 to P14 as well as cells
grown subsequently in AZT-free media (P17–P19). The 24-kDa
band indicates the presence of active protein in cultures that
have been either unexposed (control) or exposed to AZT for
24 h. Reduction in protein band intensity is apparent during
subsequent passages 9–14 with AZT in the medium and
passages 17–19 with no AZT. The inactive dimeric form,
however, remains unchanged through P14 (Fig. 4). Cells at P15–
P19, which were grown in AZT-free media after 14 passages of
AZT exposure, exhibited a persistent loss of the TK-1
monomeric and dimeric forms and gain of a tetrameric
96-kDa form (Fig. 4). Figure 5b shows monomeric forms of
TK-1 at P1 and P6 exposed to 5, 10, and 50lM AZT. PU
represents parallel untreated cultures sacriﬁced at either P1 or
P6. The reduction of the 24-kDa form is visible at P6 but not at
P1 with the low doses used in this experiment (representative of
three experiments). Protein load is revealed by the actin loading
control.
TK-1 Enzyme–Speciﬁc Activity
The oligomerization of TK-1, from monomer to dimer and
tetramer, prompted us to investigate TK-1 phosphorylation–
speciﬁc activity, and the data are shown in Figure 1 (solid
triangles). An 80% decrease in TK-1 activity was observed in
MOLT-3 cells at P1 in the presence of 800lM AZT. During 13
consecutive passages, in which cells were cultured in the
presence of 800lM AZT, TK-1 activity remained near
the assay limit of detection (Fig. 1, Table 2). A plot of the
relationship between the phosphorylation activity of TK-1 and
time to conﬂuence is shown in Figure 1, with insets indicating
TK-1 protein levels determined by Western blot at P1,P 3,P 5,
and P12. The Western blot insets also show that the drop in
TABLE 1
Cell Cycle Analysis (ﬂow cytometry) for MOLT-3 Cells Exposed
to 800mM AZT for 14 Passages and No Drug for an Additional
10 Passages
Control (P0)P 1 P14 P24
% Cells in G1 46.5 ± 0.9 30.0 ± 2.6* 41.8 ± 3.4* 42.9 ± 1.0*
% Cells in S 42.7 ± 1.9 57.3 ± 3.0* 46.0 ± 2.5* 46.2 ± 0.9*
% Cells in G2 11.4 ± 1.6 12.7 ± 0.5 12.1 ± 1.0 11.1 ± 0.2
Note. *p Values < 0.05 (Student’s t-test). Values are mean ± SD for three
experiments where AZT-exposed cells at P1,P 14, and P24 were compared to the
unexposed control.
TABLE 2
Comparison of Cell Cycle, Doubling Time, MN, and AZT-DNA Incorporation in P0,P 1,P 5, and P14 MOLT-3 Cells
Exposed to 800mM AZT
Passage Time to conﬂuence (days) S-phase (% cells)* TK-1 activity (%) TK-1 24-kDa AZT/DNA
a
MN/1000
b cells
10lM AZT
b,** 800lM AZT***
P0 1 43 100 þþþ 04 9
P1 65 7 1 8 þþ 95 6 20
P5 25 0 0 þ 175 13 38
P14 24 6 0   95 10 35
P24–27 24 6 N A   0— 8
Note. NA, not assayed.
aMeasured in molecules AZT/10
6 nucleotides.
bANOVA: p ¼ 0.0001 control (PU: average of untreated controls for P1,P 4,P 5, and P14) versus 10lM AZT P1,P 4,P 5, and P14.
*p < 0.05 for P1,P 14, and P24 compared to P0 (Student’s t-test).
**p < 0.016 for P1, 0.008 for P5, and 0.002 for P14 compared to P0 (Student’s t-test).
***p < 0.02 for P1, 0.0002 for P5, and 0.0001 for P14 compared to P0 (Student’s t-test).
AZT EXPOSURE ON HUMAN LYMPHOBLASTOID CELLS 113doubling time was accompanied by a loss of TK-1 monomeric
protein (Fig. 1,P 1–P5, and Fig. 5a).
Phosphorylation of Thymidine during Cell Growth
The data above suggested that in the presence of 800lM
AZT, thymidine tri-phosphate (TTP) for DNA replication
was provided predominantly from the de novo rather than the
salvage pathway. To further assess this point, control cells
and cells continually exposed to 800lMA Z Ta tv a r i o u s
passages were incubated with [
3H]-thymidine for 30 min, and
the conversion to [
3H]-thymidine mono-phosphate, thymi-
dine di-phosphate, and TTP was determined as described in
‘‘Materials and Methods’’ section. In the control cells, 60%
of the label was phosphorylated, mostly to TTP (47%). After
one passage in the presence of AZT, only a small amount of
TTP (< 4% of total) was detected. At later passages, there
was no detectable conversion of [
3H]-thymidine to [
3H]-TTP
(data not shown).
Table 2 provides a summary of all the data presented in this
paper. The doubling changes were similar to the percentage of
cells in S-phase in that the cell cycle slowed immediately upon
encountering the drug and subsequently (  P5) shifted more
toward normal. The TK-1–speciﬁc activity, in parallel with the
TK-1 monomeric form, was completely depleted beyond P5.
However, the AZT-DNA incorporation and MN values were
still high at P14 in the absence of active TK-1 and were only
decreased after AZT was removed from the media.
DISCUSSION
The antiretroviral nucleoside analog AZT becomes in-
corporated intracellularly into the nascent HIV-1 viral DNA
via reverse transcriptase and into the host DNA via classical
polymerases (Furman et al.,1 9 8 6 ). Prior to this incorporation,
the drug must be phosphorylated by TK-1, thymidylate kinase,
and nucleoside diphosphate kinase (Furman et al., 1986). In
this report, an inhibition of TK-1 protein expression and
activity was found to correlate with length of long-term AZT
exposure in human lymphoblastoid MOLT-3 cells (Table 2).
Incorporation of AZT into DNA, and more general DNA
damage revealed by MN, were observed during AZT exposure
and decreased to background levels when AZT was removed
from the medium. The lack of dose response seen with AZT
incorporation into the DNA MOLT-3 cells could be explained
by the fact that these cells are derived from a patient who had
received prior multidrug chemotherapy and has unusually high
terminal deoxynucleotidyl transferase activity.
Cells cultured for 14 passages with 800lM AZT exhibited
inhibition of TK-1 protein and phosphorylation activity along
with cell cycle delay. Finally, when AZT was removed from
the medium, active TK-1 did not recover and the cell cycle
parameters did not return to normal, even though indicators of
DNA damage, AZT incorporation, and MN returned to
background levels. The dose used for most of the experiments
presented here, 800lM AZT, is the highest dose with low
cytotoxicity observed in this cell line. This high dose was
employed in order to reveal mechanisms of AZT-induced
FIG. 4. TK-1 Western blot of MOLT-3 cells exposed to 0 (P0) or to 800lM AZT (P1–P14) and cells grown subsequently (P17–P19) in the absence of AZT. The
ﬁgure shows location of the active 24-kDa TK-1 and the inactive 48-kDa and 96-kDa forms of the enzyme as well as the actin loading control. This is
a representative blot of three similar repeat experiments.
FIG. 5. (a) TK-1 Western blot of MOLT-3 cells exposed to 0 (P0)o rt o
800lM AZT for 1, 3, 5, 7, 9, 13, and 15 passages. The ﬁgure shows location of
the active 24-kDa TK-1 and the inactive 48-kDa form of the enzyme as well
as the actin loading control. Bands of this blot have been used in Figure 1.
(b) TK-1 Western blot of MOLT-3 cells exposed to 0 (PU) or to 5, 10, and
50lM AZT for 1 and 6 passages. The ﬁgure shows location of the active
24-kDa TK-1 as well as the actin loading control.
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human plasma of HIV-1–infected patients, we also found
signiﬁcant DNA damage (Fig. 3).
In agreement with the previous ﬁndings that only the
monomeric form of TK-1 performs active phosphorylation
(Sherley and Kelly, 1988), we observed a TK-1 phosphorylat-
ing activity on the part of the 24-kDa form of TK-1 (Fig. 1).
The activity and the monomer disappeared after ﬁve passages
of exposure to 800lM AZT and were not restored in further
passages. In addition, the expression of the inactive dimeric
form (48 kDa) remained unchanged as time of exposure to
AZT increased (Fig. 1). Moreover, after AZT removal, the
monomeric form was undetectable, the dimeric form was
dramatically reduced, and a tetrameric form of 96 kDa became
evident (Fig. 4, right panel). A modest reduction was observed
when cells were exposed long term to lower doses as observed
in Figure 5b.
Using a recombinant TK-1 model, others support the
concept of a catalytically effective, ATP inducible tetrameric
form with higher activity than the dimeric form (Munch-
Petersen, 2009). Inhibition of TK-1 activity by AZT exposure
has been reported in T-lymphocytic cells (Avramis et al., 1993)
and attributed to hypermethylation of the TK-1 promoter (Wu
et al., 1995). Inhibition of the TK-1 enzyme has been reported
to occur in HIV-1–infected patients (Antonelli et al., 1996;
Jacobsson et al., 1995, 1998; Turriziani and Antonelli, 2004)a s
well. Antonelli et al. (1996) reported that 10 patients exposed
to therapeutic doses of AZT for 6 months exhibited a signiﬁcant
reduction in the phosphorylation efﬁciency of the enzyme
TK-1.
In H9 cells, the DNA methylation inhibitor 5-azacytidine
reversed AZT-induced downregulation of TK-1, again suggest-
ing that TK-1 hypermethylation may account for the decreased
TK-1 gene expression (Groschel et al., 2002; Hoever et al.,
2003). However, those reports do not discuss the form of the
enzyme inhibited or the changes in oligomerization taking
place after treatment.
Our data suggest that AZT induces the dimerization of the
24-kDa form (Fig. 4). Western blot analysis of long-term
MOLT-3 cells exposed to 800lM AZT revealed the presence
of a 24-kDa form and a 48-kDa form at earlier passages similar
to the forms found in untreated cells. However, when exposure
reached ﬁve passages, the 24-kDa form became undetectable
and the 48-kDa form remained present. Furthermore, the only
form present after removal of the drug for three to ﬁve passages
was the 96-kDa tetramer (Fig. 4).
Interestingly, although TK-1 is considered to be the rate-
limiting step in AZT incorporation into DNA, we measured
incorporation at P14, several passages after both the TK-1
activity and the monomer protein were undetectable. Three
possible scenarios could explain this dichotomy. First, although
undetectable by Western blots, low levels of TK-1 protein
could have been sufﬁcient to phosphorylate AZT that was been
incorporated into DNA. Second, incorporation taken place at
earlier passages, when an active form of TK-1 was present,
could have remained in the DNA without being removed by
DNA repair mechanisms and could have been present in later
passages, perhaps in those cells with impaired or reduced cell
division capacity. Finally, the nuclear encoded mitochondrial
pyrimidine deoxynucleoside salvage enzyme TK-2, involved in
pyrimidine nucleoside phosphorylation, could have been
responsible for AZT phosphorylation in the absence of TK-1.
Evidence of a phosphorylation activity for that enzyme has
been reviewed by Eriksson et al. (2002), indicating that
analogs, such as AZT, arabinofuranosylthymine, 3#-ﬂuoro-
2#,3#-deoxythymidine, and ribothymidine, could be phosphor-
ylated but with relatively low efﬁciency. Evidence of this
activity has been reported elsewhere utilizing transgenic mice
that individually expressed pathogenetic point mutants of
human TK-2 (Kohler et al., 2008). TK-2 is constitutively
expressed along the cell cycle and often is virtually the only
thymidine kinase that is physiologically active in nonprolifer-
ating and resting cells (Perez-Perez et al., 2008). To rule out
nucleotide pool imbalances, experiments were performed
employing equimolar concentrations of thymidine to study
analysis of cell cycle and other end points. Results (Yu et al.,
2009) indicated that the doses of NRTIs used had no effect on
the nucleotide pool.
It does not appear at the level of transcription, that salvage
pathways have been activated, since the expression of the
genes involved in this pathway, determined by microarray at
P1,P 5, and P14, was unchanged in cells exposed after long term
to AZT (data not shown).
Cell cycle abnormalities induced by AZT have been
previously reported in human HeLa (Olivero et al., 2005),
HL60 (Roskrow and Wickramasinghe, 1990), and Jurkat cells
(Wu et al., 2004). Prior studies performed in our laboratory,
using HeLa cells, revealed a delay in the cell cycle, with
a dose-related signiﬁcant increase in percentage of S-phase cell
accumulation after 24 h of exposure to 63–500lM AZT. At
500lM AZT, there was a twofold increase in cells in S-phase.
Here, we showed that AZT causes an accumulation of cells in
S-phase accompanied by a decrease of cells in G1 phase (Table 1).
This difference was observed in cells exposed for 1 or 14
passages and was persistent for 10 passages after the drug was
removed (P24, Table 1). No difference was observed in the G2-
phase between the percentage of unexposed cells and AZT-
exposed cells, for any of the passages analyzed.
In summary, this study showed that indicators of DNA
damage, AZT-DNA incorporation, MN, and S-phase arrest
occur in MOLT-3 cells exposed to AZT continuously for 15
passages, and only the S-phase arrest is not completely
reversible in cells subsequently grown in AZT-free media.
The study also showed that continuous AZT exposure resulted
in an early (P5) complete downregulation of the TK-1 24-kDa
protein accompanied by a loss in the ability of TK-1 to
phosphorylate AZT. The losses were not reversible at later
passages after AZT was removed from the media. The data
AZT EXPOSURE ON HUMAN LYMPHOBLASTOID CELLS 115showing AZT-induced DNA damage in the absence of active
TK-1 were unexpected and requires explanation. The role of
chronic AZT exposure as a modulator of TK-1 oligomerization
and functional capacity could be relevant to AZT resistance in
patients treated long term.
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